In 2022, Davey MG and associates published a systematic review in Breast Cancer (Auckl) regarding the involvement of miRNA in forecasting responses to neoadjuvant therapy in HER2/neu-enriched molecular subtype breast cancer [83]. The gene discussed is ERBB2; the disease is breast carcinoma.